• Breaking down case studies of progressing ADC development across Phase I-III clinical trails
• Delving into exposure response modeling and analysis to inform ADC dosing and clinical activity
• Finding the right patient for the right ADC: evaluating when and how to implement patient cut-off criteria 

Workshop leader to be announced